Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics (Nasdaq: VRDN) announced the approval of inducement grants for six new employees. The grants consist of non-qualified stock options to purchase 150,600 shares of common stock, effective November 1, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments. The exercise price equals the closing price on the grant date. These grants were made outside the company's Amended and Restated 2016 Equity Incentive Plan but follow its terms and conditions, in accordance with Nasdaq Listing Rule 5635(c)(4).
Viridian Therapeutics (Nasdaq: VRDN) ha annunciato l'approvazione di concessioni di incentivi per sei nuovi dipendenti. Le concessioni consistono in opzioni su azioni non qualificate per l'acquisto di 150.600 azioni ordinarie, con effetto dal 1 novembre 2024. Le opzioni matureranno nel corso di quattro anni, con il 25% che maturerà dopo un anno e il resto che matura in 36 rate mensili. Il prezzo di esercizio corrisponde al prezzo di chiusura alla data di concessione. Queste concessioni sono state effettuate al di fuori del Piano di Incentivi Azionari Modificato e Riformulato 2016 dell'azienda, ma seguono i suoi termini e condizioni, conformemente alla Regola di Quotazione Nasdaq 5635(c)(4).
Viridian Therapeutics (Nasdaq: VRDN) anunció la aprobación de concesiones de inducción para seis nuevos empleados. Las concesiones consisten en opciones sobre acciones no calificadas para comprar 150,600 acciones ordinarias, con fecha efectiva del 1 de noviembre de 2024. Las opciones se consolidarán durante cuatro años, con un 25% consolidándose después de un año y el resto consolidándose en 36 cuotas mensuales. El precio de ejercicio es igual al precio de cierre en la fecha de concesión. Estas concesiones se realizaron fuera del Plan de Incentivos de Capital Modificado y Reestablecido de 2016 de la empresa, pero siguen sus términos y condiciones, de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
Viridian Therapeutics (Nasdaq: VRDN)은 여섯 명의 신규 직원에 대한 유인 보상의 승인을 발표했습니다. 이 보상은 150,600주를 구매할 수 있는 비정규 주식 옵션으로 구성되며, 2024년 11월 1일부터 시행됩니다. 옵션은 4년에 걸쳐 분할로 지급되며, 1년 후 25%가 부여되고 나머지 36개월 동안 매달 지급됩니다. 행사 가격은 보상일의 종가와 같습니다. 이 보상은 회사의 수정된 2016년 주식 인센티브 계획 외에서 이루어졌지만, Nasdaq 상장 규칙 5635(c)(4)에 따라 해당 조건과 조항을 따릅니다.
Viridian Therapeutics (Nasdaq: VRDN) a annoncé l'approbation de subventions d'incitation pour six nouveaux employés. Les subventions consistent en des options d'actions non qualifiées permettant d'acheter 150 600 actions ordinaires, avec effet à partir du 1er novembre 2024. Les options acquerront des droits sur quatre ans, avec 25 % acquérant des droits après un an et le reste acquérant des droits en 36 versements mensuels. Le prix d'exercice est égal au prix de clôture à la date de la subvention. Ces subventions ont été attribuées en dehors du Plan d'Incitation en Actions 2016 modifié et reformulé de l'entreprise, mais suivent ses termes et conditions, conformément à la Règle d'Inscription Nasdaq 5635(c)(4).
Viridian Therapeutics (Nasdaq: VRDN) gab die Genehmigung von Anreizgewährungen für sechs neue Mitarbeiter bekannt. Die Gewährungen bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 150.600 Stammaktien, die ab dem 1. November 2024 wirksam sind. Die Optionen reifen über einen Zeitraum von vier Jahren, wobei 25% nach einem Jahr reifen und der Rest in 36 monatlichen Raten. Der Ausübungspreis entspricht dem Schlusskurs am Gewährungstag. Diese Gewährungen wurden außerhalb des geänderten und neu gefassten 2016 Equity Incentive Plans des Unternehmens vorgenommen, folgen jedoch dessen Bedingungen gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Stock-based compensation structure helps attract and retain talent without immediate cash expenditure
- Potential future shareholder dilution from 150,600 new stock options
The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105032921/en/
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
How many shares were granted in Viridian Therapeutics' (VRDN) November 2024 inducement grants?
What is the vesting schedule for Viridian Therapeutics' (VRDN) November 2024 inducement grants?
How many employees received Viridian Therapeutics' (VRDN) November 2024 inducement grants?
